Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > LATEST
LATEST
-
ORGANIZATION OTC Industry Head Urges Caution on Extra Charges for “OTC-Like” Drugs
January 20, 2026
-
REGULATORY AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
January 20, 2026
-
REGULATORY Japan’s Lower House Poll Set for Feb. 8 after Takaichi Calls Snap Vote
January 20, 2026
-
REGULATORY Daiichi, University of Tokyo Professor Win Japan’s PM Award for Ezharmia Development
January 20, 2026
-
ORGANIZATION JETRO Picks 10 Overseas Startups for Regenerative Medicine Japan Entry Program
January 20, 2026
-
BUSINESS Kaken’s Hyperhidrosis Drug Ecclock Now Available in South Korea
January 20, 2026
-
BUSINESS Daridorexant Hits Primary Goal in South Korea PIII Insomnia Trial, Nxera Plans Filing in Q1 2026
January 20, 2026
-
BUSINESS Enhertu Combo Accepted for EU Review in First-Line HER2 Breast Cancer
January 20, 2026
-
REGULATORY Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead
January 19, 2026
-
REGULATORY Chuikyo OKs 3.5% Minimum NHI Price Hike, Sets Grace Period for New AG Pricing
January 19, 2026
-
BUSINESS Oncolys Aims for First-Line Use of Telomelysin in Esophageal Cancer
January 19, 2026
-
REGULATORY Antivirals, Cancer Drugs Flagged in PMDA Risk Review
January 19, 2026
-
BUSINESS 3D Plans to Lift Toho Stake to Up to 27%
January 19, 2026
-
BUSINESS Nobelpharma Launches Pediatric Sleep Aid Melatonin in China
January 19, 2026
-
REGULATORY Bosulif, 4 Other Drugs Escape April Re-Pricing as “Spillover” Scrapped; Lixiana, Entresto Brace for Cuts
January 19, 2026
-
REGULATORY Japan Panel to Review Pfizer’s Cancer Med Tukysa on January 29
January 16, 2026
-
BUSINESS iPark Institute to Launch AI-Based Platform to Link Investors with Startups
January 16, 2026
-
BUSINESS Acromegaly Drug Palsonify Meets Primary Endpoint in Japan PII/PIII Trial
January 16, 2026
-
REGULATORY Study Group Calls for Independent Body to Centrally Manage Whole Genome Data
January 16, 2026
-
BUSINESS Tanabe’s EPP/XLP Drug Hits Main Goals in PIII, Weighs Launch Strategy
January 16, 2026
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…